September 24: The Week in Cancer News
Long-term COVID-19 effects were associated with greater mortality risk in cancer patients, and more news of the week from Cancer Today.
Progress Against Cancer
Long-term COVID-19 effects were associated with greater mortality risk in cancer patients, and more news of the week from Cancer Today.
With targeted drugs, immunotherapies and treatment combinations now available, people with advanced melanoma have choices to make.
Treatments for small cell lung cancer have remained virtually the same for decades. Now, experts say that hope is on the horizon.
High-grade glioma, a kind of brain tumor, is difficult to treat and often fatal in children and adolescents.
Liquid biopsy tests can find tiny amounts of disease that remain after surgery and chemotherapy.
KRAS mutations were once thought to be resistant to drug therapy.
THE FDA GRANTED ACCELERATED APPROVAL TO A NEW THERAPY FOR ADVANCED CERVICAL CANCER The U.S. Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv (Tidvak) for patients with cervical cancer that has...
An immunotherapy combination continues to be effective in treating kidney cancer patients, and more news of the week from Cancer Today.
Blood cancer patients are highly vulnerable to COVID-19 infection. Now mounting evidence suggests they may be also among the least protected by vaccines. Blood Cancer Discovery, a journal of the American Association for Cancer Research (AACR), has recently published studies investigating the...
The FDA approved a tyrosine kinase inhibitor for certain patients with thyroid cancer. The U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) for adult and pediatric patients 12 years of age and older...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More